The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.

A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for ...

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging ...

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) announced opinions for three ...

Researchers at the USC Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute are advancing a new treatment for dry age-related macular degeneration, a leading cause of ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation ...

USC is leading a research team aiming to better understand retinitis pigmentosa and inform future treatments.

HALT, pairs Amarna’s SV40-derived gene delivery vector platform with Phenocell’s in vitro AMD disease model, which accurately ...

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of ...